Leukaemia & Blood Cancer New Zealand welcomes Pharmac’s proposal to widen access to pembrolizumab (Keytruda) for Hodgkin lymphoma and bendamustine for chronic lymphocytic leukaemia, as these are highly beneficial therapies for the patients that need them.
As Pharmac continues to work through the allocation of its recent budget uplift, we hope to see meaningful prioritisation of blood cancer medicines on the Options for Investment list. Many of these medicines have significant clinical benefits and form standard clinical practice internationally.
LBC will be making a submission on behalf of blood cancer patients, but your voice can also be heard by providing feedback directly to Pharmac via email: consult@pharmac.govt.nz by 4pm Friday 26 July 2024.
For further details, refer to the Pharmac consultation page:
lymphoma – https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-immunotherapy-for-six-types-of-cancer-and-treatments-to-prevent-fungal-infections